Abbott Laboratories (NYSE:ABT) SVP Eric Shroff Sells 709 Shares

Abbott Laboratories (NYSE:ABT) SVP Eric Shroff sold 709 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $113.55 on Wednesday. The stock has a market cap of $197.31 billion, a PE ratio of 30.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.74. The stock has a 50-day moving average of $116.90 and a 200-day moving average of $125.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA approval of the redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader aimed at improving patient convenience and clinician workflows — strengthens Abbott’s position in heart‑failure management and could increase adoption and revenue over time. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Multiple insider sales disclosed (several senior/executive officers sold small blocks of shares on Mar. 2). The transactions were modest relative to their remaining holdings, suggesting routine portfolio management rather than a clear signal of company deterioration. John A. Jr. Mccoy Insider Sale
• Negative Sentiment: Near-term earnings pressure: Q4 EPS met estimates but revenue came in below consensus ($11.46B vs. ~$11.80B), which, together with recent softer quarterly trends, has left analysts cautious and weighed on the stock. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Shares have underperformed the market over the past six months amid disappointing near‑term results and investor skepticism, which increases sensitivity to any incremental downside news. 2 Reasons to Like ABT and 1 to Stay Skeptical

Analysts Set New Price Targets

A number of research firms recently issued reports on ABT. Daiwa Securities Group lowered their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Barclays lowered their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Weiss Ratings downgraded Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $137.05.

Institutional Trading of Abbott Laboratories

A number of institutional investors have recently modified their holdings of ABT. Brighton Jones LLC increased its stake in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC increased its stake in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the last quarter. United Bank raised its holdings in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares in the last quarter. GHP Investment Advisors Inc. lifted its position in shares of Abbott Laboratories by 0.8% during the 2nd quarter. GHP Investment Advisors Inc. now owns 29,713 shares of the healthcare product maker’s stock worth $4,041,000 after buying an additional 222 shares during the last quarter. Finally, Versor Investments LP bought a new position in Abbott Laboratories in the second quarter valued at about $408,000. 75.18% of the stock is currently owned by institutional investors.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.